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c o r r e s p o n d e n c e
Shorter Moxifloxacin-Based Regimens for Drug-Sensitive 
Tuberculosis
To the Editor: Gillespie et al. (Oct. 23 issue)1 
report that two moxifloxacin-containing regi-
mens for the treatment of tuberculosis were not 
effective with a shortened treatment period of 
4 months. The authors used a moxifloxacin dose 
of 400 mg per day, which may have contributed 
to the unfavorable results. Rifampin decreases 
the average exposure to moxifloxacin (assessed 
according to the area under the curve [AUC]) by 
approximately 30%,2 which can be compensated 
for by an increase in the dose of moxifloxacin.3 
In addition, preclinical data combined with 
pharmacokinetic and pharmacodynamic model-
ing showed that a higher moxifloxacin dose, of 
800 mg per day, is likely to achieve better Myco-
bacterium tuberculosis microbial killing and sup-
pression of drug resistance.4 Limited data have 
shown that moxifloxacin at a dose of 800 mg can 
be given safely.3,5 The inclusion of moxifloxacin 
drug exposure as a covariate would have been of 
additional value, considering that the ratio of the 
AUC to the minimum inhibitory concentration is 
the driver of moxifloxacin efficacy and that the 
AUC for moxifloxacin can vary among patients 
by a factor of 7.6 Such a pharmacokinetic and 
pharmacodynamic analysis could have shown 
whether the results of this trial could have been 
explained by a drug exposure to moxifloxacin 
that was too low.
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To the Editor: The Rapid Evaluation of Moxi-
floxacin in Tuberculosis (REMoxTB) study did 
not show the noninferiority of two moxifloxacin-
containing regimens, shortened to 4 months, as 
compared with a control regimen, for the treat-
ment of tuberculosis. Failures during the treat-
ment phase occurred in less than 2% of patients. 
More unfavorable outcomes in the two groups 
with shorter regimens, as compared with the 
control group, were driven by more relapses after 
conversion to culture-negative status after the end 
of treatment. Relapse strains were those shown to 
be identical on 24-locus mycobacterial-interspersed-
repetitive-unit (MIRU) analysis. First, whole-
genome sequencing enables the differentiation 
between relapse and reinfection with greater 
resolution than MIRU analysis.1 Second, differ-
entiation between relapse and reinfection with 
the same strain from a close relative2 might be 
impossible if the diversity of circulating clones is 
limited.3 Reinfection with the same strain from a 
close relative can occur frequently 4 in areas with 
a high prevalence of tuberculosis (where this study 
was conducted). The results could be different in 
areas with a low prevalence of tuberculosis.
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The Authors Reply: We agree that an increased 
dose of moxifloxacin might be of interest and 
has proved to be valuable in patients with limited 
treatment options. We aimed to register a new 
shortened regimen for susceptible disease, and 
our approach was to repurpose an existing li-
censed preparation at its approved dose. This 
strategy has the advantage that the safety charac-
teristics of all the regimen components were well 
understood. Because the proposed 800-mg dose 
is outside the current license and the adverse-
event profile among an unselected population is 
unpredictable, the incorporation of such a dose 
would require intensive preclinical and clinical 
testing before it could be used in a regulatory 
phase 3 study. Moreover, as shown in Table S3B 
in the Supplementary Appendix, available with the 
full text of the article at NEJM.org, patients receiv-
ing moxifloxacin who had a higher body-mass 
index (BMI) had a better outcome than did those 
with a low BMI, which argues against the sup-
position that a higher dose might have been suc-
cessful. This result contrasts with the OFLOTUB 
study, in which the opposite was found.1
Next-generation whole-genome sequencing 
provides increased granularity to differentiate 
relapse from reinfection, as we found in a subset 
of patients from the REMoxTB cohort.2 Among 
the many sensitivity analyses that we performed, 
we evaluated the effect of calling all reinfections 
“unfavorable” (instead of “not able to be as-
sessed”), which resulted in proportions of un-
favorable outcomes of 17%, 25%, and 26% in the 
control, isoniazid, and ethambutol groups, re-
spectively. Thus, this different interpretation did 
not alter the overall outcome of the study. 
Whole-genome sequencing will have an impor-
tant effect on our understanding of tuberculosis 
infection, and these insights will have conse-
quences for the design of clinical trials. Simi-
larly, enumerating the number of mixed infec-
tions and improving recognition of laboratory 
cross-contamination could reduce sample size.
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